Researchers Identify Liver Fibrosis Signaling Pathway
The discovery of an FTO-mediated mechanism provides a new target for future liver fibrosis therapies.
Updated on Oct. 25, 2026 in Life Sciences
Live Poll
Should government funding prioritize basic research into molecular disease mechanisms to develop new medical treatments?
Researchers have identified a molecular pathway in liver fibrosis involving the FTO protein and m6A methylation. This discovery outlines how FTO deficiency contributes to cellular activation and mitochondrial dysfunction in a research-stage model.
Why it matters
Understanding this signaling axis reveals how gene expression control through methylation regulates liver scarring. The finding highlights a potential molecular target for future therapeutic strategies in treating chronic liver disease.
The study demonstrates that FTO depletion leads to increased m6A methylation and elevated levels of TRIB3 via IGF2BP1. These changes trigger mitochondrial dysfunction and promote the expression of fibrotic markers like collagen type I.
The details
Hepatic stellate cells — liver cells that store vitamin A — typically become activated during fibrosis, leading to excess collagen production. The research shows that the FTO protein acts as a regulator; its absence removes a check on m6A methylation, a chemical modification of RNA. This dysregulation increases TRIB3, a protein that interferes with cellular metabolism, causing mitochondrial damage and accelerating tissue scarring.
Timeline
October 25, 2026: Article publication
The Tech Race
This study maps the specific role of the FTO-m6A-IGF2BP1-TRIB3 axis in hepatic stellate cell biology. It follows a growing trend of research focusing on m6A methylation regulators as key drivers of tissue-specific pathology.
This discovery is currently limited to laboratory models and does not offer immediate clinical applications for patients. It provides a foundational target for researchers to develop potential diagnostic or treatment pathways for liver scarring in the future.
The takeaway
The research establishes a clear link between FTO deficiency and fibrotic mitochondrial dysfunction. Future studies will need to determine if small-molecule inhibitors or gene therapies can successfully modulate this axis in clinical settings.
Further reading
Explore deeper insights into metabolic regulation and cellular repair mechanisms in our Life Sciences section.
More information
View the full results of the scientific research study published in Nature.
Source note: This article includes information reported by Nature.
Live Poll
Should government funding prioritize basic research into molecular disease mechanisms to develop new medical treatments?
